Nuvo Pharmaceuticals announces Health Canada approves Suvexx for the acute treatment of migraine

Nuvo Pharmaceuticals

27 February 2020 - Canadian launch anticipated in the second half of 2020.

Nuvo Pharmaceuticals today announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada has received a Notice of Compliance from Health Canada for Suvexx. 

Suvexx (sumatriptan succinate and naproxen sodium tablets) is a fixed-dose combination prescription medication, indicated for the acute treatment of migraine attacks with or without aura in adults.

Read Nuvo Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder